Austin Church

Austin Church is an associate in Goodwin’s Business Law department and a member of its Life Sciences group. He joined Goodwin in 2023. Austin represents both public and private companies and underwriters in the biotechnology industry.

Austin’s practice covers the corporate cycle, with a focus on private financings through IPOs and public financings. He also counsels clients on a variety of corporate matters, including securities law compliance and corporate governance.

• Represented Kazia Therapeutics Limited in its $50 million private placement
• Represented Adicet Bio, Inc. in its $98 million follow-on offering
• Represented MBX Biosciences Inc. in its $200 million follow-on offering
• Represented the underwriters in connection with Nova Ltd.’s $750 million Rule 144A convertible note sale
• Represented Allurion Technologies, Inc. in connection with a $17 million follow-on offering
• Represented the underwriters in connection with BlackSky Technology Inc.’s $185 million Rule 144A convertible note sale
• Represented BofA Securities Inc., and other underwriters in connection with Metsera Inc.’s $275 million initial public offering
• Represented MBX Biosciences Inc. in its $187.7 million upsized initial public offering

During his time at Boston University School of Law, he was a member of the Boston University Law Review. He also served as a Note Editor on the Law Review.

He was a member of the BU/MIT Startup Law clinic during his time at Boston University School of Law, helping provide free legal services to student entrepreneurs. 

Author, “Note: Incorporating a Deposit Mechanism Into the Digital Millennium Copyright Act to Fight Online Counterfeiting in E-Commerce,” Boston University Law Review, April 2023
Author, “Updates on Pending Legislation: Citizen Petitions,” Big Molecule Watch Blog, July 2022